EUCTR2010-023110-30-GB进行中（未招募）不适用
An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases - OCTOME Study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Aged 18 or above
- •2.Ability to provide informed consent
- •3.Diagnosis of macular oedema secondary to diabetic maculopathy, branch and central retinal vein occlusion or pseudophakic cystoid macular oedema or post inflammatory macular oedema
- •4.Central macular thickness on OCT should be above 250µm
- •5.Best corrected visual acuity in the study eye between 37 and 68 letters
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any other eye disease which could mask macular oedema
- •2.Known uncontrolled systemic disease or current immunosuppressive disease.
- •3.Initiation of medical therapy for diabetes or a change from oral hypoglycaemic agents to insulin therapy within 4 months prior to the screening visit
- •4.Renal failure requiring haemodialysis or peritoneal dialysis within 6 months prior to screening visit
- •5.Any ocular condition in the study eye that in the opinion of the investigator would prevent a 15-letter improvement in visual acuity (e.g., severe macular ischemia, extensive macular laser scarring or atrophy)
- •6.Presence of an epiretinal membrane or vitreo-retinal interface changes in the study eye which, in the opinion of the investigator, is the primary cause of macular oedema, or is severe enough to prevent improvement in visual acuity despite reduction in macular oedema
- •7.Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
- •8.Advanced glaucoma which cannot be adequately controlled by medicinal products alone.
- •9.History of IOP elevation in response to steroid treatment in either eye that resulted in any of the following:
- •a)>10 mm Hg increase in IOP from baseline with an absolute IOP > 25 mm Hg
- •b)required therapy with 3 or more anti-glaucoma medications
- •10.Pregnancy if child bearing age (confirmed by pregnancy test) and to avoid pregnancy during the 36 weeks of the study. Pregnancy test will not be done in post-menopausal women (defined as 12 months post LMP). Breast feeding women will be excluded.
- •11.Hypersensitivity to the active substance or to any of the excipients.
- •12.Inability to provide informed consent
研究者
相似试验
已完成
3 期
OCTOME studyISRCTN66216819King's College NHS Foundation Trust (UK)30
进行中（未招募）
1 期
A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate to severe atopic dermatitis.Atopic dermatitisEUCTR2020-004194-51-PLMedical University of Lodz317
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseAdult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 24.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2019-000954-67-ITAMICUS THERAPEUTICS, INC.120
招募中
3 期
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe DiseaseGlycogen storage disease type II10028396Pompe diseaseNL-OMON54552Amicus Therapeutics1
进行中（未招募）
1 期
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseAdult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 24.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2019-000954-67-BEAmicus Therapeutics, Inc.110